Javascript must be enabled to continue!
Chromosomal Instability (CIN) Phenotype, CIN High or CIN Low, Predicts Survival for Colorectal Cancer
View through CrossRef
Purpose
To examine whether chromosomal instability (CIN) phenotype, determined by the severity of CIN, can predict survival for stages II and III colorectal cancer (CRC).
Patients and Methods
We determined microsatellite instability (MSI) and loss of heterozygosity (LOH) status in 1,103 patients (training [n = 845] and validation [n = 258] sets with stages II and III CRC). The LOH ratio was defined as the frequency of LOH in chromosomes 2p, 5q, 17p, and 18q. According to the LOH ratio, non–MSI high tumors were classified as CIN high (LOH ratio ≥ 33%) or CIN low (LOH ratio < 33%). CIN-high tumors were subclassified as CIN high (mild type; LOH ratio < 75%) or CIN high (severe type; LOH ratio ≥ 75%). We used microarrays to identify a gene signature that could classify the CIN phenotype and evaluated its ability to predict prognosis.
Results
CIN high showed the worst survival (P < .001), whereas there was no significant difference between CIN low and MSI high. CIN high (severe type) showed poorer survival than CIN high (mild type; P < .001). Multivariate analysis revealed that CIN phenotype was an independent risk factor for disease-free and overall survival, respectively, in both the training (P < .001 and P = .0155) and validation sets (P < .001 and P = .0076). Microarray analysis also revealed that survival was significantly poorer in those with the CIN-high than in the CIN-low gene signature (P = .0203). In a validation of 290 independent CRCs (GSE14333), the CIN-high gene signature showed significantly poorer survival than the CIN-low signature (P = .0047).
Conclusion
The CIN phenotype is a predictive marker for survival and may be used to select high-risk patients with stages II and III CRC.
American Society of Clinical Oncology (ASCO)
Title: Chromosomal Instability (CIN) Phenotype, CIN High or CIN Low, Predicts Survival for Colorectal Cancer
Description:
Purpose
To examine whether chromosomal instability (CIN) phenotype, determined by the severity of CIN, can predict survival for stages II and III colorectal cancer (CRC).
Patients and Methods
We determined microsatellite instability (MSI) and loss of heterozygosity (LOH) status in 1,103 patients (training [n = 845] and validation [n = 258] sets with stages II and III CRC).
The LOH ratio was defined as the frequency of LOH in chromosomes 2p, 5q, 17p, and 18q.
According to the LOH ratio, non–MSI high tumors were classified as CIN high (LOH ratio ≥ 33%) or CIN low (LOH ratio < 33%).
CIN-high tumors were subclassified as CIN high (mild type; LOH ratio < 75%) or CIN high (severe type; LOH ratio ≥ 75%).
We used microarrays to identify a gene signature that could classify the CIN phenotype and evaluated its ability to predict prognosis.
Results
CIN high showed the worst survival (P < .
001), whereas there was no significant difference between CIN low and MSI high.
CIN high (severe type) showed poorer survival than CIN high (mild type; P < .
001).
Multivariate analysis revealed that CIN phenotype was an independent risk factor for disease-free and overall survival, respectively, in both the training (P < .
001 and P = .
0155) and validation sets (P < .
001 and P = .
0076).
Microarray analysis also revealed that survival was significantly poorer in those with the CIN-high than in the CIN-low gene signature (P = .
0203).
In a validation of 290 independent CRCs (GSE14333), the CIN-high gene signature showed significantly poorer survival than the CIN-low signature (P = .
0047).
Conclusion
The CIN phenotype is a predictive marker for survival and may be used to select high-risk patients with stages II and III CRC.
Related Results
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract
Introduction: Current study found that about one-third of the incidence of colorectal cancer have genetic related. Hereditary nonpolyposis colorectal cancer...
Chromosomal Instability: A Probable Unfavorable Prognostic Factor For Patients Of Myeloidysplastic Syndromes
Chromosomal Instability: A Probable Unfavorable Prognostic Factor For Patients Of Myeloidysplastic Syndromes
Abstract
Objective
Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoetic stem cell clonal disorders with a h...
Development of a plasma cell-free DNA chromosome instabilities assay for early cancer detection and treatment response monitoring of multiple tumor types.
Development of a plasma cell-free DNA chromosome instabilities assay for early cancer detection and treatment response monitoring of multiple tumor types.
e13072 Background: Tumor cells keep shedding DNA into blood stream. Here we present a retrospective study to investigate the potential of CIN in plasma cell-free DNA (cfDNA) as a ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Abstract 5777: Functional role of PLK1 in colorectal cancer progression and its potential to chemoresistance
Abstract 5777: Functional role of PLK1 in colorectal cancer progression and its potential to chemoresistance
Abstract
OBJECTIVE:
Colorectal cancer is a cancer with high prevalence and mortality rates worldwide, treated with surger...
Abstract 1844: Centriole amplification sensitizes cells to paclitaxel
Abstract 1844: Centriole amplification sensitizes cells to paclitaxel
Abstract
Paclitaxel (Taxol) is a widely utilized treatment for primary and metastatic breast cancer. However, only about 50% of patients respond and no predictive bi...

